Samsung halts clinical tests for rituximab biosimilar

October 18, 2012 6:21 AM

Samsung, the South Korean industry giant, was planning to launch their own biosimilars by 2015 but it seems a part of this plan is halted due to some internal reasons. 

Samsung Electronics’ aspirations to find a new growth engine in biotechnology and pharmaceuticals appear to have hit a speed bump. Company officials admit that it has halted clinical tests for SAIT101, a material it hoped would create more effective drugs to fight Hodgkin’s disease.

The company had been testing the potential drug material in 16 countries, including Britain, Spain, Czech Republic, Canada, Brazil, South Africa and Taiwan aside of Korea.

It appears that Samsung is being forced to redo the tests from scratch due to changes in safety requirements in Europe and the United States. The U.S. in particular has recently announced new guidelines for the research of biopharmaceuticals, or medical drugs produced using biotechnology.

The Samsung source, who is close to the projects, said that the company is in talks with the U.S. FDA to reset the conditions for the SAIT101 clinical tests.

“We had vowed to get quicker approval in Europe, so this will definitely put us behind our original schedule. There was also a need to better prepare for testing in the U.S. which is even a larger market. We will eventually be fine,” he said.

Samsung plans to invest more than $2 billion by 2020 in the area of biotechnology and advanced pharmaceuticals, which it believes will eventually grow to complement its main cash cows of mobile phones, consumer electronics, semiconductors and flat screens.

Samsung Electronics Chairman Lee Kun-hee has been vocal about the company carving a position in biopharmaceuticals, which he believes would be a good fit for Samsung’s traditional business model based on manufacturing prowess and brute strength.

The global market for biopharmaceuticals is seen currently at around $30 billion and expected to maintain annual growth rate of over 50 percent during 2010-15 period.

The market will be propelled by upcoming patent expiries of leading biologics and a financial crisis coupled with increasing health care costs that has required systems in almost all developed countries to look for low-cost alternatives, Samsung officials said.

 

Source: The Korea Times

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!